Cargando…

Development and content validity testing of a patient-reported outcomes questionnaire for the assessment of hereditary angioedema in observational studies

BACKGROUND: Hereditary Angioedema (HAE), a rare genetic disease, manifests as intermittent, painful attacks of angioedema. Attacks vary in frequency and severity and include skin, abdominal and life-threatening laryngeal swellings. This study aimed to develop a patient reported outcome (PRO) tool fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonner, Nicola, Abetz-Webb, Linda, Renault, Lydie, Caballero, Teresa, Longhurst, Hilary, Maurer, Marcus, Christiansen, Sandra, Zuraw, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487558/ https://www.ncbi.nlm.nih.gov/pubmed/26129930 http://dx.doi.org/10.1186/s12955-015-0292-7

Ejemplares similares

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema
por: Vanya, Magdalena, et al.
Publicado: (2023)

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
por: Longhurst, Hilary
Publicado: (2018)

Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

Correction to: Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema
por: Vanya, Magdalena, et al.
Publicado: (2023)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema
por: Bygum, Anette, et al.
Publicado: (2017)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
por: Bork, Konrad, et al.
Publicado: (2021)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

Correction to: Mitigating Disparity in Healthcare Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019)

Summary and Conclusions: New Perspectives in Hereditary Angioedema: Molecular Mechanisms and Therapeutic Choices: A CME Symposium Presented at the World Allergy Congress, Buenos Aires, Argentina (December 2009)
por: Zuraw, Bruce L
Publicado: (2010)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable
por: Longhurst, Hilary J, et al.
Publicado: (2023)

Management of hereditary angioedema in pregnant women: a review
por: Caballero, Teresa, et al.
Publicado: (2014)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
por: Bowen, Tom, et al.
Publicado: (2010)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
por: Zuraw, B. L., et al.
Publicado: (2015)

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Hereditary angioedema: quality of life in Brazilian patients
por: Gomide, Maria Abadia Consuelo M S, et al.
Publicado: (2013)

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1sv9puap40a7o0npnf9hpfkkfp